Effects of Nitrogen Mustard and Cyclophosphamide Upon the Synthesis of DNA in Vivo and in Cell—Freepreparations'

Total Page:16

File Type:pdf, Size:1020Kb

Effects of Nitrogen Mustard and Cyclophosphamide Upon the Synthesis of DNA in Vivo and in Cell—Freepreparations' [CANCER RESEARCH 29, 98—109,January 1969] Effects of Nitrogen Mustard and Cyclophosphamide upon the Synthesis of DNA in Vivo and in Cell—freePreparations' Glynn P. Wheelerand Jo Ann Alexander Kettering-Meyer Laboratory2, Southern Research Institite, Birmingham, Alabama 35205 SUMMARY and concentrations of the nitrogen mustard, it was possible to inhibit the synthesis of DNA more than that of RNA and to Single doses of nitrogen mustard or cyclophosphamide inhibit synthesis in a sensitive tumor without inhibiting caused regression of plasmacytomas in hamsters and decreases synthesis in a bilaterally growing resistant tumor. Other in the rate of synthesis of DNA and RNA by the tumors. studies (23) showed that multidose treatment of hamsters Maximum inhibition of synthesis did not occur immediately bearing plasmacytomas with cyclophosphamide [2-[bis(2- following the administration of the agent but was observable chloroethyl)amino]-2H-1,3,2-oxazaphosphorinane 2-oxide] 24—48 hours later. This inhibition was accompanied by a de caused decreases in the activity of DNA nucleotidyltransferase crease in DNA nucleotidyltransferase activity of crude cell-free and of thymidylate kinase of soluble cell fractions prepared supernatant fractions prepared from the treated tumors. from the plasmacytomas, but that a single dose of cyclophos The concentrations of nitrogen mustard required for in vitro phamide given 2 hours before killing the animal caused an deactivation of the crude DNA nucleotidyltransferase and for increase of the DNA nucleotidyltransferase activity. These in vitro deactivation of commercial salmon sperm DNA as a results provoked the questions whether the observed decreased primer for this system were much greater than those that synthesis of DNA in vivo and the decreased nucleotidykrans would be present in hamsters following the administration of ferase activity were the cumulative effects of multiple doses of therapeutically effective doses. It was concluded that neither the agents, whether similar effects would be observed at longer the direct deactivation of the DNA nucleotidyltransferase nor intervals after the administration of single doses of the drugs, gross interference with the primer activity of DNA is the cause and whether decreased nucleotidyltransferase activity is a pri of the observed therapeutic effect upon the tumor or the de mary or secondary effect of the drug. In pursuit of answers to crease of synthesis of DNA in vivo. these questions, we have now performed experiments to: (a) Transient inhibition of growth and of synthesis of DNA and determine the relationship between the interval after admin RNA by drug-resistant tumors was also observed. It is not istering a single dose of nitrogen mustard or cyclophosphamide presently known whether the resumption of growth and and the effect upon the synthesis of nucleic acids in vivo, (b) synthesis of nucleic acids is the result of repair of damage and determine the effects of treatment of cell-free preparations recovery by the cells or of killing and elimination of the cells from plasmacytomas with nitrogen mustard upon the DNA of the tumor that are most sensitive to the agent. It is evident, nucleotidyltransferase activity, (c) determine the effects of however, that inhibition of the synthesis of DNA and RNA by treatment of DNA with nitrogen mustard in vitro upon the a tumor during the first 48 hours following administration of priming activity of the DNA for the DNA nucleotidyltrans nitrogen mustard or cyclophosphamide cannot be considered ferase system, and (d) compare the effects of in vivo treatment to be indicative that a favorable therapeutic effect of the agent with cyclophosphamide upon the in vivo synthesis of DNA by has been accomplished. plasmacytomas and upon the DNA nucleotidyltransferase activity of a cell-free preparation from the same plasmacy INTRODUCTION tomas. Previous studies in this laboratory (27) have shown that MATERIALS AND METhODS nitrogen mustard (HN2) inhibits the incorporation of radio active substrates into DNA by Fortner hamster plasmacytomas Determination of the Effects of Agents upon the Growth of in vivo and by minces of these tumors. With selected dosages Tumors. Trocar implants of cyclophosphamide-sensitive (9) and cyclophosphamide-resistant (22) plasmacytomas were placed subcutaneously and bilaterally in the axillary regions of 1ThiS investigation was supported by the Cancer Chemotherapy young (45- to 55-gram) Syrian hamsters. Fourteen days later National Service Center, National Cancer Institute, USPHS, under con tract PH43-66-29 and by grants from the Charles F. Kettering Founda single intraperitoneal injections of the respective agents were tion and the Alfred P. Sloan Foundation, Inc. administered, and daily measurements of the tumors were 2Afflliated with Sloan-Kettering Institute for Cancer Research, New made by means of calipers. Approximations of the weights of York, New York. the tumors were made with the assumption that the tumors Received April 9, 1968 ; accepted September 15, 1968. were prolate spheroids with a density of 1.0. 98 CANCER RESEARCH VOL.29 Downloaded from cancerres.aacrjournals.org on September 26, 2021. © 1969 American Association for Cancer Research. Effects ofNitrogen Mustard and Cyclophosphamide Determination of the Effects of Agents upon the Fixation of In the standard procedure, the reaction mixture minus the ‘4Cfrom Formate-'4C and from Adenine-8-14C. Hamsters primer was incubated at 37°Cfor 10 minutes, and the primer bearing bilaterally and subcutaneously growing 13-day-old and was then added. The time at which the primer was added is 1 4-day-old cyclophosphamide-sensitive and cyclophospha hereafter referred to as zero time. In certain experiments the mide-resistant plasmacytomas were given single intraperitoneal enzyme preparation or a solution of native salmon sperm DNA injections of nitrogen mustard or cyclophosphamide at speci was incubated with or without nitrogen mustard and then used fled doses. At intervals thereafter, the animals were given intra in the standard procedure. At zero time and at designated peritoneal injections of sodium formate-14 C (specific activity, intervals (each 10 minutes during the first hour, each 20 min 55, 220, or 298 jic per mg; dosage, 1 pc per gram of body utes during the second hour, and each 30 minutes during the weight) or adenine-8-14C (specific activity, 21.7, 83.3, or 129 third and fourth hours) during the ensuing 4 hours, [email protected] Ilc per mg; dosage, 0.3 @scper gram of body weight). The samples of the incubation mixtures were transferred to discs of animals were killed by carbon dioxide asphyxiation 2 hours filter paper and allowed to dry at room conditions, whereupon following the injection of the radioactive compounds. The the discs were dropped into a beaker of cold 5 percent tri tumors from 3 or 4 animals were pooled; homogenates, alco chloroacetic acid. The beaker contained at least 10 ml of the holic extracts, and the purines of RNA and of DNA were acid solution for each disc. The discs were allowed to stand prepared and assayed for radioactivity by procedures that have overnight in the acidic solution and were then washed two been described (28). times by standing for 15 minutes in cold 5 percent solutions of Preparation of Soluble Extracts of Tissues. Hamsters bearing trichloroacetic acid. The discs were next washed once with 14-day-old subcutaneous plasmacytomas were asphyxiated cold absolute ethanol and allowed to dry on paper towels at with carbon dioxide, and the tumors were removed and placed room conditions. The quantities of 14C present on the discs in ice-cold containers. After the tumors were minced freehand were determined with a Packard Tri-Carb scintillation spec with knives and forced through the perforated steel plate of a trometer, and it was assumed that the 14C was present in tissue press, 10 grams of the tissue were homogenized by DNA. means of a Thomas Tissue Grinder with a motor-driven teflon At the same times that samples of the incubation mixtures pestle in 30 ml of an ice-cold aqueous solution that was 0.25 were taken for placing upon the paper discs, other samples of M with respect to sucrose and 0.02 M with respect to Tris 10 ;.zl each were spotted on Whatman No. 1 paper for subse hydrochloride buffer (pH 8.0). This homogenate was centri quent chromatography using isobutyric acid:water:acetic acid fuged at 105,000 X g for 1 hour. The aqueous supernatant (100:50:1 v/v/v) as the solvent. The positions of the radio layer was removed by pipet, care being taken to exclude the active spots were detected by means of blue-sensitive X-ray overlying lipid layer. This solution was assayed for protein by film, and the radioactive areas were cut from the chromato the method of Lowry et a!. (16) and was used without further grams and assayed with the liquid scintillation spectrometer. treatment as the source of enzymes for the incubations. The identities of the various radioactive components of the Incubation Mixtures and Enzyme Assays. Each sample for mixtures were determined by comparison of the RF values incubation contained the following ingredients at the indicated with those of known compounds that were chromatographed concentrations in micromoles per ml: sucrose, 222; Tris in parallel with them. hydrochloride buffer (pH 7.5), 8.8; adenosine triphosphate, Determination of the Effects of a Single Dose of Cyclophos 1.1 ; magnesium chloride, 1.1 ; potassium chloride, 40; potas phamide or Nitrogen Mustard upon the in Vivo Fixation of 3H slum phosphoenolpyruvate, 5.04; and pyruvate kinase, 0.84 from Thymidine-C3H3 by Plasmacytomas and upon the DNA microgram per ml. Each sample also contained either the Nucleotidyltransferase Activity of the Same Tumors. Ham monophosphates or triphosphates of deoxyadenosine, deoxy sters bearing 14-day-old subcutaneously growing plasmacy guanosine, deoxycytidine, and thymidine at concentrations of tomas were given single injections of cyclophosphamide (20 0.046 micromole per ml.
Recommended publications
  • Page 1 EXAMPLES of ACUTE TOXINS (By CAS#) APPENDIX V(H)-B
    EXAMPLES OF ACUTE TOXINS (by CAS#) APPENDIX V(h)-B Key: SA -- Readily Absorbed Through the Skin Revised: 12/2012 ___________________________________________________ _____________ _________________________ | | | CHEMICAL NAME CAS # | SA | TARGET ORGAN | ___________________________________________________ ____________ | _ | _______________________ | AFLATOXINS 000000-00-0 | | systemic | ANILINE AND COMPOUNDS 000000-00-0 | x | blood | ARSENIC ACID AND SALTS 000000-00-0 | x | systemic | ARSENIUOS ACID AND SALTS 000000-00-0 | | systemic | ARSONIC ACID AND SALTS 000000-00-0 | | systemic | BOTULINUM TOXINS 000000-00-0 | | systemic | CYANIDE AND COMPOUNDS 000000-00-0 | x | blood | CYANOGEN AND COMPOUNDS 000000-00-0 | | blood | METHYL MERCURY AND COMPOUNDS 000000-00-0 | x | CNS | VENOM, SNAKE, CROTALUS ADAMANTEUS 000000-00-0 | | systemic | VENOM, SNAKE, CROTALUS ATROX 000000-00-0 | | systemic | MITOMYCIN C 000050-07-7 | | systemic | DINITROPHENOL, 2,4- 000051-28-5 | x | systemic | ATROPINE 000051-55-8 | x | CNS | HN2 (NITROGEN MUSTARD-2) 000051-75-2 | x | systemic | THIOTEPA 000052-24-4 | | systemic | NICOTINE 000054-11-5 | x | CNS | NITROGEN MUSTARD HYDROCHLORIDE 000055-86-7 | x | systemic | PARATHION 000056-38-2 | x | CNS | CYANIDE 000057-12-5 | x | blood | STRYCHNINE 000057-24-9 | | systemic,CNS | TUBOCURARINE CHLORIDE HYDRATE,(+)- 000057-94-3 | x | systemic | METHYL HYDRAZINE 000060-34-4 | x | pulmonary,CNS,blood | ANILINE 000062-53-3 | x | blood | DICHLORVOS 000062-73-7 | x | systemic | SODIUM FLUOROACETATE 000062-74-8 | x | systemic | COLCHICINE
    [Show full text]
  • The Chemotherapy of Malignant Disease -Practical and Experimental Considerations
    Postgrad Med J: first published as 10.1136/pgmj.41.475.268 on 1 May 1965. Downloaded from POSTGRAD. MED. J. (1965), 41,268 THE CHEMOTHERAPY OF MALIGNANT DISEASE -PRACTICAL AND EXPERIMENTAL CONSIDERATIONS JOHN MATTHIAS, M.D., M.R.C.P., F.F.A., R.C.S. Physician, The Royal Marsden Hospital, London, S.W.3. THE TERM chemotherapy was introduced by positively charged alkyl (CH2) radicles of Ehrlich to describe the specific and effective the agent. treatment of infectious disease by chemical (a) The nitrogen mustards: mustine (HN2 substances. It is currently also applied to the 'nitrogen mustard', mechlorethamine, treatment of malignant disease. Unfortunately mustargen), trimustine (Trillekamin no aspect of tumour metabolism has been HN3), chlorambucil (Leukeran, phenyl discovered which has allowed the development butyric mustard), melphalan (Alkeran, of drugs capable of acting specifically upon the phenyl alanine mustard), uramustine malignant cell, so that cytotoxic drugs also (Uracil mustard), cyclophosphamide affect normal cells to a greater or lesser degree. (Endoxan or Cytoxan), mannomustine The most susceptible or sensitive of the normal (DegranoO). tissues are those with the highest rates of cell (b) The ethylenamines: tretamine (trie- turnover and include the haemopoietic and thanomelamine, triethylene melamine, lympho-reticular tissues, the gastro-intestinal TEM), thiotepa (triethylene thiopho- the the testis and the hair epithelium, ovary, sphoramide), triaziquone (Trenimon).by copyright. follicles. (c) The epoxides: triethyleneglycoldigly- Cancer chemotherapy may be said to encom- cidyl ether (Epodyl). pass all treatments of a chemical nature (d) The sulphonic acid esters: busulphan administered to patients with the purpose of (Myleran), mannitol myleran. restricting tumour growth or destroying tumour 2.
    [Show full text]
  • Cancer Drug Pharmacology Table
    CANCER DRUG PHARMACOLOGY TABLE Cytotoxic Chemotherapy Drugs are classified according to the BC Cancer Drug Manual Monographs, unless otherwise specified (see asterisks). Subclassifications are in brackets where applicable. Alkylating Agents have reactive groups (usually alkyl) that attach to Antimetabolites are structural analogues of naturally occurring molecules DNA or RNA, leading to interruption in synthesis of DNA, RNA, or required for DNA and RNA synthesis. When substituted for the natural body proteins. substances, they disrupt DNA and RNA synthesis. bendamustine (nitrogen mustard) azacitidine (pyrimidine analogue) busulfan (alkyl sulfonate) capecitabine (pyrimidine analogue) carboplatin (platinum) cladribine (adenosine analogue) carmustine (nitrosurea) cytarabine (pyrimidine analogue) chlorambucil (nitrogen mustard) fludarabine (purine analogue) cisplatin (platinum) fluorouracil (pyrimidine analogue) cyclophosphamide (nitrogen mustard) gemcitabine (pyrimidine analogue) dacarbazine (triazine) mercaptopurine (purine analogue) estramustine (nitrogen mustard with 17-beta-estradiol) methotrexate (folate analogue) hydroxyurea pralatrexate (folate analogue) ifosfamide (nitrogen mustard) pemetrexed (folate analogue) lomustine (nitrosurea) pentostatin (purine analogue) mechlorethamine (nitrogen mustard) raltitrexed (folate analogue) melphalan (nitrogen mustard) thioguanine (purine analogue) oxaliplatin (platinum) trifluridine-tipiracil (pyrimidine analogue/thymidine phosphorylase procarbazine (triazine) inhibitor)
    [Show full text]
  • Salvage Chemotherapy for Recurrent Primary Brain Tumors in Children
    Salvage chemotherapy for recurrent primary brain tumors in children Jan van Eys, PhD, MD, Tallie Z. Baram, MD, PhD, Ayten Cangir, MD, Janet M. Bruner, MD, and J. Martinez-Prieto, MD From the Departments of Pediatrics, Neurooncology, and Pathology, The Universityof Texas M, D. Anderson Cancer Center at Houston Sixty consecutive evaluable children with recurrent primary tumors of the central nervous system were treated with a regimen of vincristine, nitrogen mustard, procarbazine, and prednisone over a 12-year period. Tumor types included medulloblastoma (19), brain-stem glioma (16), astrocytoma (13), and a miscellaneous glioma (12). Responses and sustained survivals were achieved. Responses were highly dependent on tumor type. Disease progres- sion was halted in 73% of the children with medulloblastoma, and three have survived in complete remission for more than 10 years from the start of therapy with vincristine, nitrogen mustard, procarbazine, and prednisone. Two of four patients with anaplastic glioma, are long-term survivors. In contrast, less than one third of children with brain-stem gliomas responded. Toxicity consisted mainly of neutropenia, thrombocytopenia, infections, and rarely a procarba- zine rash. (J PEDIAI'R1988;113:601-6) Therapy for recurrent brain tumors in children remains METHODS unsatisfactory; most die of their disease regardless of Patients. Sixty-five children with a median age of 6 therapy, l We have repbrted on the responsiveness of years (range, 1 to 16 years) were treated with MOPP for recurrent brain tumors in children to chemotherapy with recurrent brain tumors. Sixty patients were eligible for vincristine, nitrogen mustard, procarbazine, and predni- evaluation; the other five patients were excluded because 1 sone.
    [Show full text]
  • Anticancer Alkylating Agents-Part-I.Pdf
    Anticancer Agents Medicinal Chemistry III B Pharm Dr. bilal al-jaidi Assistant Professor, Pharmaceutical Medicinal Chemistry Faculty of Pharmacy, Philadelphia University-Jordan Email: [email protected] Learning Outcome At the end of this lesson students will be able to – Outline the current status, causes and treatment strategies of cancer – Explain the mechanism of action, SAR, therapeutic uses and side effects of following classes of anti-cancer agents: • Alkylating Agents QUIZ = 20 Marks • Heavy metal compounds (Metallating Agents) • Anti-metabolite • Antibiotics • Plant Extracts • Topoisomerase inhibitors • Hormones • Combination of chemotherapy with other treatments • Others First Examination= 20 Marks The Status of Cancer • Cancer is a leading cause of death worldwide, accounting for 12.6 million new cases and 7.6 million deaths every year. THIS IS EQUIVALENT TO ONE PERSON, EVERY 5 SECONDS OF EVERYDAY Source: GLOBOCAN 2008 By 2020 the World Health Organisation (WHO) expects this rise to 16 million. Cancer • A new growth of tissue in which multiplication of cells is uncontrolled and progressive (tumour). • Abnormal cells can spread to other parts of the body (metastasise). Cancer Types Cancer types are categorized based on the functions/locations of the cells from which they originate: Carcinoma: a tumor derived from epithelial cells, those cells that line the inner or outer surfaces of our skin and organs (80-90% of all cancer cases reported) Sarcoma: a tumor derived from muscle, bone, cartilage, fat or connective tissues. Leukemia: a cancer derived from white blood cells or their precursors. Lymphoma: a cancer of bone marrow derived cells that affects the lymphatic system. Myelomas: a cancer involving the white blood cells responsible for the production of antibodies (B lymphocytes).
    [Show full text]
  • The Nitrogen Mustard Anticancer Agent Mechlorethamine Generates Cross-Links Deri
    Article pubs.acs.org/biochemistry A New Cross-Link for an Old Cross-Linking Drug: The Nitrogen Mustard Anticancer Agent Mechlorethamine Generates Cross-Links Derived from Abasic Sites in Addition to the Expected Drug-Bridged Cross-Links Maryam Imani Nejad,† Kevin M. Johnson,† Nathan E. Price,† and Kent S. Gates*,†,‡ † Department of Chemistry, University of Missouri, 125 Chemistry Building, Columbia, Missouri 65211, United States ‡ Department of Biochemistry, University of Missouri, 125 Chemistry Building, Columbia, Missouri 65211, United States *S Supporting Information ABSTRACT: Nitrogen mustard anticancer drugs generate highly reactive aziridinium ions that alkylate DNA. Mono- adducts arising from reaction with position N7 of guanine residues are the major DNA adducts generated by these agents. Interstrand cross-links in which the drug bridges position N7 of two guanine residues are formed in low yields relative to those of the monoadducts but are generally thought to be central to medicinal activity. The N7-alkylguanine residues generated by nitrogen mustards are depurinated to yield abasic (Ap) sites in duplex DNA. Here, we show that Ap sites generated by the nitrogen mustard mechlorethamine lead to interstrand cross-links of a type not previously associated with this drug. Gel electrophoretic data were consistent with early evolution of the expected drug-bridged cross-links, followed by the appearance of Ap-derived cross-links. The evidence is further consistent with a reaction pathway involving alkylation of a guanine residue in a 5′-GT sequence, followed by depurination to generate the Ap site, and cross-link formation via reaction of the Ap aldehyde residue with the opposing adenine residue at this site [Price, N.
    [Show full text]
  • Covalent Protein Adduction of Nitrogen Mustards and Related Compounds Vanessa R
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 2-28-2014 Covalent Protein Adduction of Nitrogen Mustards and Related Compounds Vanessa R. Thompson Florida International University, [email protected] DOI: 10.25148/etd.FI14040835 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Amino Acids, Peptides, and Proteins Commons, and the Analytical Chemistry Commons Recommended Citation Thompson, Vanessa R., "Covalent Protein Adduction of Nitrogen Mustards and Related Compounds" (2014). FIU Electronic Theses and Dissertations. 1152. https://digitalcommons.fiu.edu/etd/1152 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida COVALENT PROTEIN ADDUCTION OF NITROGEN MUSTARDS AND RELATED COMPOUNDS A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Vanessa Thompson 2014 To: Dean Kenneth G. Furton College of Arts and Sciences This dissertation, written by Vanessa Thompson, and entitled Covalent Protein Adduction of Nitrogen Mustards and Related Compounds, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Fenfei Leng _______________________________________ Watson Lees _______________________________________ Dietrich Lorke _______________________________________ Bruce McCord _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: February 27, 2014 The dissertation of Vanessa Thompson is approved.
    [Show full text]
  • Nitrogen Mustard Hydrochloride Exposure to Other Drugs, Or Were Based on Small Numbers of Exposed Cases (Zaridze Et Al
    Report on Carcinogens, Fourteenth Edition For Table of Contents, see home page: http://ntp.niehs.nih.gov/go/roc Nitrogen Mustard Hydrochloride exposure to other drugs, or were based on small numbers of exposed cases (Zaridze et al. 1993). CAS No. 55-86-7 Properties Reasonably anticipated to be a human carcinogen Nitrogen mustard hydrochloride is a compound analogous to mus- First listed in the Fourth Annual Report on Carcinogens (1985) tard gas, with sulfur replaced by nitrogen. It exists at room temper- Also known as nitrogen mustard, mechlorethamine, or ature as white to off-white crystals or powder with a fishy odor. It mechlorethamine hydrochloride is soluble in water and ethanol. The dry crystals are stable at room temperature, but unstable in aqueous solution (IARC 1975). Physi- CH3 H2 H2 cal and chemical properties of nitrogen mustard hydrochloride are C N C listed in the following table. Cl C C Cl HCl H2 H2 Property Information Carcinogenicity Molecular weight 192.5a Specific gravity 1.118 g/cm3 at 25°Cb Nitrogen mustard hydrochloride is reasonably anticipated to be a Melting point 109°C to 111°Ca human carcinogen based on sufficient evidence of carcinogenicity Boiling point 87°C at 18 mm Hgb a from studies in experimental animals. In the literature, the names Log Kow –1.24 “nitrogen mustard” and “nitrogen mustard hydrochloride” are used Water solubility 10g/La Dissociation constant (pK ) 6.43 at 25°Ca interchangeably. Only nitrogen mustard hydrochloride is produced a commercially, so it is assumed that nitrogen mustard hydrochloride Sources: aHSDB 2009, bChemIDplus 2009.
    [Show full text]
  • Evaluation of Melphalan, Oxaliplatin, and Paclitaxel in Colon, Liver, And
    ANTICANCER RESEARCH 33: 1989-2000 (2013) Evaluation of Melphalan, Oxaliplatin, and Paclitaxel in Colon, Liver, and Gastric Cancer Cell Lines in a Short-term Exposure Model of Chemosaturation Therapy by Percutaneous Hepatic Perfusion RAJNEESH P. UZGARE, TIMOTHY P. SHEETS and DANIEL S. JOHNSTON Pharmaceutical Research and Development, Delcath Systems, Inc., Queensbury, NY, U.S.A. Abstract. Background: The goal of this study was to candidates for use in the CS-PHP system to treat patients determine whether liver, gastric, or colonic cancer may be with gastric and colonic metastases, and primary cancer of suitable targets for chemosaturation therapy with the liver. percutaneous hepatic perfusion (CS-PHP) and to assess the feasibility of utilizing other cytotoxic agents besides Chemotherapeutic molecules exert beneficial clinical effects melphalan in the CS-PHP system. Materials and Methods: by inhibiting cell growth or by inducing cell death via Forty human cell lines were screened against three cytotoxic apoptosis. They can be divided into several categories based chemotherapeutic agents. Specifically, the dose-dependent on their mechanisms of action. The chemotherapeutic agent effect of melphalan, oxaliplatin, and paclitaxel on melphalan hydrochloride, which has been approved by the proliferation and apoptosis in each cell line was evaluated. US Food and Drug Administration and is used in the These agents were also evaluated for their ability to induce treatment of multiple myeloma and ovarian cancer, is a apoptosis in normal primary human hepatocytes. A high- derivative of nitrogen mustard that acts as a bifunctional dose short-term drug exposure protocol was employed to alkylating agent. Melphalan causes the alkylation of DNA at simulate conditions encountered during CS-PHP.
    [Show full text]
  • NITROGEN MUSTARD by OLIVER GARAI, M.R.C.P
    Postgrad Med J: first published as 10.1136/pgmj.24.272.307 on 1 June 1948. Downloaded from 307 NITROGEN MUSTARD By OLIVER GARAI, M.R.C.P. Clinical Assistant to the Department of Medicine, King's College Hospital, London Introduction et al. in 1936 (I. Berenblum, 1936) found that The nitrogen mustards are closely related mustard gas depressed the glycolysis of minced chemically to the mustard gas notorious in tumour tissue. The significance of this finding chemical warfare. The former differs from its is tempered by their report that Ethylene-bis-b military ancestor only in that the sulphur of the chloroethylsulphide which also inhibits carceno- latter is replaced by a nitrogen-containing group. genesis possess no selective action on glycolysis. Sulphur mustard becomes nitrogen mustard, thus: The introduction of radio-active isotopes for research purposes, made possible a great advance CH2CH2C1. in determining the fate of the mustards in living / tissue. Most of this work and, in fact, all research Mustard gas S work on the mustards which was in progress at the outbreak of World War II, was intensified and CH2CH2C1. at once came under strict secrecy. It was not CH2CHCH1. until I946 that papers concerning the mustards / began to be published once again. Much of the becomes work that had been carried out over the interveningby copyright. CH3N war years was reviewed by Gilman and Phillips in April, 1946, and by Haddow in 1947. Details CH2CH2C1. of the biochemistry and pharmacology of the History mustards were published by Banks et al. in a series Knowledge of the effects produced by bis- of papers in I946.
    [Show full text]
  • Trolox Enhances the Anti-Lymphoma Effects of Arsenic Trioxide, While Protecting Against Liver Toxicity
    Leukemia (2007) 21, 2117–2127 & 2007 Nature Publishing Group All rights reserved 0887-6924/07 $30.00 www.nature.com/leu ORIGINAL ARTICLE Trolox enhances the anti-lymphoma effects of arsenic trioxide, while protecting against liver toxicity Z Diaz1,2, A Laurenzana1,2, KK Mann1,2, TA Bismar1,2,3, HM Schipper2,4 and WH Miller Jr1,2 1Segal Cancer Centre and Lady Davis Institute for Medical Research, McGill University, Montreal, Que´bec, Canada; 2Department of Oncology, McGill University, Montreal, Que´bec, Canada; 3Department of Pathology, McGill University, Montreal, Que´bec, Canada and 4Department of Neurology and Neurosurgery, McGill University, Montreal, Que´bec, Canada Arsenic trioxide (As2O3) is an effective therapy in acute in vivo studies characterized the effectiveness of arsenic in promyelocytic leukemia (APL), but its use in other malignancies various hematological malignancies, and multiple phase I/II is limited by the higher concentrations required to induce apoptosis. We have reported that trolox, an analogue of clinical trials are underway to evaluate its feasibility, safety and potential efficacy. Arsenic has also been tested in non- a-tocopherol, increases As2O3-mediated apoptosis in a variety of APL, myeloma and breast cancer cell lines, while non- hematological cancer. Using an orthotopic prostate metastasis malignant cells may be protected. In the present study, we model, As2O3 alone provided a dose-dependent inhibition of extended previous results to show that trolox increases As2O3- both primary and metastatic lesions, although an increased mediated apoptosis in the P388 lymphoma cell line in vitro,as survival rate was only obtained in the group treated with the evidenced by decrease of mitochondrial membrane potential combination of As2O3 and buthionine sulfoxamine (BSO), an and release of cytochrome c.
    [Show full text]
  • First FDA-Approved Chemo Agent Turns 60
    18 ONCOLOGY MARCH 1, 2009 • INTERNAL MEDICINE NEWS First FDA-Approved Chemo Agent Turns 60 BY BETSY BATES more chemotherapy drugs for the treatment of a wide range of dif- History of Chemotherapy: A Time Line “The response of the first patient was as dramatic as that of ferent malignancies.” the first mouse. ...Within 48 hours after the initiation of ther- The journey has been anything apy, a softening of the tumor masses was detected. It soon but smooth, with strong early op- First use of mustard gas on 1917 became obvious that this was not just wishful thinking.” position documented by Yale on- the battlefield, WWI. —Alfred Gilman, Ph.D., “The Initial Clinical Trial of Ni- cologists Vincent T. DeVita Jr. trogen Mustard” (Amer. J. Surg. 1963;105:574-8). and Edward Chu in a recent arti- cle, “A History of Cancer he top-secret intravenous administration of 0.1 Chemotherapy” (Cancer Res. Aitken 2nd Lt. T.L. United Kingdom Government 1942 Secret contract signed mg/kg “Compound X” to an “x-ray resistant pa- 2008;68:8643-53). “Remissions between U.S. Office of Ttient in the terminal stages of lymphosarcoma” turned out to be brief and in- Scientific Research and Yale in early December 1942 marked the quiet birth of complete, and this realization University to study chemical chemotherapy in America. then created an air of pessimism Library and Archives Canada warfare agents; animal research begins. The clandestine, government-sanctioned treatment that pervaded the subsequent lit- Bari Incident: Mustard gas 1943 of an anonymous patient at Yale University, New erature of the 1950s,” they noted.
    [Show full text]